Posted by Michael Wonder on 27 May 2025
Eylea 8 mg with extended 6 month treatment interval recommended for approval in EU
23 May 2025 - CHMP opinion is based on the findings from the pivotal clinical trials PULSAR in neovascular (wet) age-related macular degeneration and PHOTON in diabetic macular oedema.
Bayer announced today that the CHMP of the EMA has issued a positive opinion recommending a label extension for Eylea 8 mg (aflibercept 8 mg, 114.3 mg/mL solution for injection).
